EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An update on the pharmacotherapy of postpartum depression

J Arifunhera, R Mirunalini iD

International Journal of Gynecology & Obstetrics · 2025-03 · 168 (3) · 933-943

DOI: 10.1002/ijgo.15980 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 04.11.2024. Verfasst von J Arifunhera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, JIPMER, Pondicherry, India. Hauptthemen laut MEDLINE: Depression, Postpartum, Antidepressive Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensive research has been conducted on postpartum depression (PPD) over the past century, and yet no definitive answer regarding its etiopathogenesis, risk factors, genetic predilection, and treatment has been found. The few preclinical and clinical studies propose that maternal brain adaptations to the endocrinological, immunological, and behavioral changes and external sociodemographic risk factors in the perinatal period make women more vulnerable to anxiety and depression. Irrespective of the cause, a dilemma exists regarding the type of help to provide postpartum mothers. With very few treatment options at our disposal, deciding between psychotherapy, pharmacological, and non‐pharmacological therapy on a case‐by‐case basis is unproductive because in developing countries infrastructure is limited and the availability of medications, especially for psychiatric illnesses, is still evolving. Hence, regardless of psychotherapy, antidepressants remain the first line of treatment with selective serotonin reuptake inhibitors (SSRIs); sertraline has the best efficacy and safety profile in breastfeeding women. As endocrine factors play a significant role in etiopathogenesis, hormonal therapy with oxytocin has been shown to be efficacious, and studies investigating the role of testosterone in treating PPD are also under way. In 2019, the US Food and Drug Administration (FDA) approved the first and only drug for the sole purpose of treating PPD, brexanolone. Zuranolone, a drug recently approved by the FDA, has a similar mechanism of action to brexanolone. For breastfeeding mothers reluctant to use pharmacotherapy, somatic therapy has been studied, including bright light therapy, vagal nerve stimulation, and newer noninvasive interventions. This article encompasses a short note on PPD, including its etiopathogenesis and clinical characteristics, and recapitulates the various available and evolving pharmacological and nonpharmacological therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depression, PostpartumAntidepressive AgentsHumansFemaleSelective Serotonin Reuptake InhibitorsPregnanolonePsychotherapyPregnancyOxytocinBreast FeedingDrug Combinationsbeta-Cyclodextrins

Stichwörter der Autor:innen

depressionetiopathogenesispostpartum depressionpostpartum motherstherapeuticstreatment

Substanzen

Antidepressive AgentsSelective Serotonin Reuptake InhibitorsPregnanolonebrexanoloneOxytocinDrug Combinationsbeta-Cyclodextrins

Autor:innen und Institutionen

  • Department of Pharmacology, JIPMER, Pondicherry, India.

ORCID-Profile: R Mirunalini

Zitieren

APA

Arifunhera, J., & Mirunalini, R. (2025). An update on the pharmacotherapy of postpartum depression. International Journal of Gynecology & Obstetrics, 168(3), 933-943. https://doi.org/10.1002/ijgo.15980

Vancouver

Arifunhera J, Mirunalini R. An update on the pharmacotherapy of postpartum depression. International Journal of Gynecology & Obstetrics. 2025;168(3):933-943. doi:10.1002/ijgo.15980

BibTeX
@article{Arifunhera2025,
  author = {Arifunhera, J and Mirunalini, R},
  title = {An update on the pharmacotherapy of postpartum depression},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2025},
  volume = {168},
  number = {3},
  pages = {933--943},
  doi = {10.1002/ijgo.15980}
}
Kostenlos starten →